What is Ping An Biomedical's earnings per share (EPS)?

Ping An Biomedical (PASW) reported diluted earnings per share of $-0.10 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ping An Biomedical Financials

PASW

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE September

This page shows Ping An Biomedical (PASW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PASW FY2025 2026-04-22

A thin gross spread and receivable-heavy working capital make this business rely on external financing instead of internally generated cash.

With only 2.8% gross margin, the company produced just $133K of gross profit, leaving ordinary overhead to drive most of the operating loss rather than a financing or tax issue. Cash conversion was less weak than earnings because operating cash outflow of -$903K was smaller than the net loss of -$1.8M, but the business still depended on external financing to keep operating.

The current ratio of 2.8x looks comfortable, but that liquidity is not sitting in cash. $2.4M of receivables versus only $165K of cash means short-term flexibility depends heavily on how quickly customers pay.

A 0.5x debt-to-equity ratio suggests the balance sheet is not dominated by leverage, so financing strain is coming more from operating losses than from creditors. $4.8M of sales turning into only $133K of gross profit means there is very little contribution margin available to absorb routine overhead.

Financial Health Signals

Financial Profile 24/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Ping An Biomedical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Ping An Biomedical has an operating margin of -43.0%, meaning the company retains $-43 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

Ping An Biomedical carries a low D/E ratio of 0.51, meaning only $0.51 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Ping An Biomedical's current ratio of 2.76 indicates adequate short-term liquidity, earning a score of 52/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Ping An Biomedical generates a -28.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Earnings Quality Low Quality

0.50x

For every $1 of reported earnings, Ping An Biomedical generates $0.50 in operating cash flow (-$903K OCF vs -$1.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-47.9x

Ping An Biomedical earns $-47.9 in operating income for every $1 of interest expense (-$2.1M vs $43K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.8M

Ping An Biomedical generated $4.8M in revenue in fiscal year 2025.

EBITDA

-$2.1M

Ping An Biomedical's EBITDA was -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$1.8M

Ping An Biomedical reported -$1.8M in net income in fiscal year 2025.

EPS (Diluted)

$-0.10

Ping An Biomedical earned $-0.10 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$165K

Ping An Biomedical held $165K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

21M

Ping An Biomedical had 21M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

2.8%

Ping An Biomedical's gross margin was 2.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.

Operating Margin

-43.0%

Ping An Biomedical's operating margin was -43.0% in fiscal year 2025, reflecting core business profitability.

Net Margin

-37.6%

Ping An Biomedical's net profit margin was -37.6% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

-28.4%

Ping An Biomedical's ROE was -28.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

PASW Income Statement

Metric	FY25
Revenue	$4.8M
Cost of Revenue	$4.7M
Gross Profit	$133K
R&D Expenses	N/A
SG&A Expenses	$844K
Operating Income	-$2.1M
Interest Expense	$43K
Income Tax	$261K
Net Income	-$1.8M
EPS (Diluted)	$-0.10

Metric	Q4'25	Q2'25
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	N/A	N/A
SG&A Expenses	N/A	N/A
Operating Income	N/A	N/A
Interest Expense	N/A	N/A
Income Tax	N/A	N/A
Net Income	N/A	N/A
EPS (Diluted)	N/A	N/A

PASW Balance Sheet

Metric	FY25
Total Assets	$9.6M
Current Assets	$8.9M
Cash & Equivalents	$165K
Inventory	$62K
Accounts Receivable	$2.4M
Goodwill	N/A
Total Liabilities	$3.3M
Current Liabilities	$3.2M
Long-Term Debt	N/A
Total Equity	$6.4M
Retained Earnings	-$3.0M

Metric	Q4'25	Q2'25
Total Assets	$9.6M+43.4%	$6.7M
Current Assets	$8.9M+40.9%	$6.3M
Cash & Equivalents	$165K+990.0%	$15K
Inventory	$62K+240.4%	$18K
Accounts Receivable	$2.4M-42.5%	$4.1M
Goodwill	N/A	N/A
Total Liabilities	$3.3M-60.9%	$8.3M
Current Liabilities	$3.2M-60.8%	$8.3M
Long-Term Debt	N/A	N/A
Total Equity	$6.4M+492.6%	-$1.6M
Retained Earnings	-$3.0M-72.3%	-$1.7M

PASW Cash Flow Statement

Metric	FY25
Operating Cash Flow	-$903K
Capital Expenditures	N/A
Free Cash Flow	N/A
Investing Cash Flow	N/A
Financing Cash Flow	$6.1M
Dividends Paid	N/A
Share Buybacks	N/A

Metric	Q4'25	Q2'25
Operating Cash Flow	N/A	N/A
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	N/A	N/A
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

PASW Financial Ratios

Metric	FY25
Gross Margin	2.8%
Operating Margin	-43.0%
Net Margin	-37.6%
Return on Equity	-28.4%
Return on Assets	-18.8%
Current Ratio	2.76
Debt-to-Equity	0.51
FCF Margin	N/A

Metric	Q4'25	Q2'25
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	N/A	N/A
Return on Assets	N/A	N/A
Current Ratio	2.76+2.0	0.77
Debt-to-Equity	0.51+5.7	-5.14
FCF Margin	N/A	N/A

Frequently Asked Questions

What is Ping An Biomedical's annual revenue?

Ping An Biomedical (PASW) reported $4.8M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Ping An Biomedical profitable?

No, Ping An Biomedical (PASW) reported a net income of -$1.8M in fiscal year 2025, with a net profit margin of -37.6%.

What is Ping An Biomedical's EBITDA?

Ping An Biomedical (PASW) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ping An Biomedical's gross margin?

Ping An Biomedical (PASW) had a gross margin of 2.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Ping An Biomedical's operating margin?

Ping An Biomedical (PASW) had an operating margin of -43.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ping An Biomedical's net profit margin?

Ping An Biomedical (PASW) had a net profit margin of -37.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ping An Biomedical's return on equity (ROE)?

Ping An Biomedical (PASW) has a return on equity of -28.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ping An Biomedical's operating cash flow?

Ping An Biomedical (PASW) generated -$903K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ping An Biomedical's total assets?

Ping An Biomedical (PASW) had $9.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Ping An Biomedical have outstanding?

Ping An Biomedical (PASW) had 21M shares outstanding as of fiscal year 2025.

What is Ping An Biomedical's current ratio?

Ping An Biomedical (PASW) had a current ratio of 2.76 as of fiscal year 2025, which is generally considered healthy.

What is Ping An Biomedical's debt-to-equity ratio?

Ping An Biomedical (PASW) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ping An Biomedical's return on assets (ROA)?

Ping An Biomedical (PASW) had a return on assets of -18.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ping An Biomedical's cash runway?

Based on fiscal year 2025 data, Ping An Biomedical (PASW) had $165K in cash against an annual operating cash burn of $903K. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Are Ping An Biomedical's earnings high quality?

Ping An Biomedical (PASW) has an earnings quality ratio of 0.50x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ping An Biomedical cover its interest payments?

Ping An Biomedical (PASW) has an interest coverage ratio of -47.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ping An Biomedical?

Ping An Biomedical (PASW) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.